SBRT vs RFA for Oligometastatic Liver Disease: British Journal of Radiology | July 2026

Introduction:

Local ablative therapy plays an important role in managing oligometastatic liver disease when surgical resection is not feasible. This review compares stereotactic body radiotherapy (SBRT) and percutaneous radiofrequency ablation (RFA), highlighting their respective advantages, limitations, and practical clinical applications.

Why was this article needed?

• Many patients with liver oligometastases are not candidates for surgical resection.
• RFA has traditionally been the preferred local ablative treatment, but SBRT is increasingly being adopted.
• Optimal treatment selection depends on tumor size, location, and patient characteristics.
• Direct comparative guidance for clinicians has been limited.
• Standardized recommendations are needed to support multidisciplinary decision-making.

Key Takeaways:

• Both SBRT and RFA provide effective local treatment for inoperable oligometastatic liver disease and can improve local tumor control and overall survival in carefully selected patients.
• RFA remains the preferred option for small, peripherally located liver metastases, particularly when lesions are technically accessible.
• SBRT is particularly advantageous for larger tumors or lesions adjacent to major blood vessels, bile ducts, or other anatomically challenging locations where RFA is technically difficult or carries a higher risk of incomplete ablation.
• SBRT offers a completely non-invasive treatment approach with excellent precision, making it an attractive option for patients who are poor candidates for invasive procedures.
• Current evidence supports both modalities, but high-quality randomized trials directly comparing SBRT and RFA remain lacking, emphasizing the need for individualized multidisciplinary treatment planning.

Clinical Impact:

The choice between SBRT and RFA should be individualized based on tumor size, anatomical location, technical feasibility, patient comorbidities, and institutional expertise. A multidisciplinary discussion involving hepatobiliary surgeons, interventional radiologists, radiation oncologists, and medical oncologists remains essential to optimize outcomes.

Bottom Line:

SBRT and radiofrequency ablation are complementary rather than competing therapies for oligometastatic liver disease. RFA is generally preferred for small, accessible lesions, whereas SBRT offers an excellent non-invasive alternative for larger or anatomically difficult tumors, expanding local treatment options for patients who are not surgical candidates.